Stansberry Venture Value pick hints lead to an obesity drug company whose "only competition is itself"
10 Comments Read MoreArticles
What’s Lashmet’s “Hunger Switch” Stock?
Friday File: NVIDIA by the Fingernails, Gold (and other shiny things), Energy Storage and more…
What do Polish groceries, Ferraris, Giant Batteries, Mine Disasters and John Maynard Keynes have in common? Well, not much, but they're all in this week's Friday File... along with a trade or two.
12 Comments Read MoreHernias, COVID, Obesity Drugs and Medicare Negotiation
Answers: Lashmet’s “Venture #87” — Teased as having the “potential for 400% Gains” starting October 31 as it “changes millions of lives”
Cancer 2023 – Second Installment
In this follow-up to the previous Doc Gumshoe missive about cancer, entitled “Cancer 2023 – What’s Happening in the Combat Zone,” which posted on July 18, we’ll be discussing several general types of cancer – brain, lung, ovarian, breast, liver, and cancer caused by obesity. In each case, however, there are special conditions associated with […]
6 Comments Read MoreCancer 2023: What’s Happening in the Combat Zone?
Just over 50 years ago, President Richard M. Nixon signed into law the National Cancer Act of 1971, which established the National Cancer Institute. Cancer had become the second leading (after heart disease) cause of death in the US in 1970. The National Cancer Institute (NCI) from its establishment had broad powers, including the creation […]
26 Comments Read MoreAlzheimer’s Disease, RSV, Migraines and more…
Answers: “The Ultimate Weight Loss Drug” teased by Eifrig’s Prosperity Investor
Finally, we take a short break from the A.I. mania to look at something else… this is the start of the pitch from Stansberry for Dr. David Eifrig’s Prosperity Investor(special deal is $2,500 for two years), with the ad introduced by Thomas Carroll, one of the analysts for that letter (John Engel is the other, […]
31 Comments Read MoreWeight and Waistline Worries
March 2023 Miscellany
Osteoporosis Update (Part Two)
Odd & Ends – October 2022
Stansberry Venture’s “Major Announcement” — What are the Three Companies facing a Wave of Money?
New ads pitch a special report called "Three Ways to Make Triple-Digit Gains on Flash-Radioimmunotherapy," and we've got the Thinkolator results ... plus, a note about the also-teased "Incredible Weight-Loss Drug"
22 Comments Read MoreFollowing Up on Your Suggestions – September 2022
Updates on Alzheimer's Disease, Anti-Inflammatories, Prostate Cancer, Vitamin D and more...
20 Comments Read MoreDe-teasing the “Takeover Target for May” pitched by Dylan Jovine
March 2022 Bulletins — Brief, but Relevant
Doc Gumshoe looks at infections, weight-loss drugs, cataracts and dementia, Vitamin D supplements and more...
23 Comments Read MoreEifrig’s “#1 Biotech Stock” and Four Teased Healthcare Plays
May Miscellany – Some Covid-19, Some Otherwise
Doc Gumshoe looks at Herd Immunity, Vaccines and Treatments... plus some updates on Alzheimer's Disease, Dementia and more...
33 Comments Read MoreDecember 2020 COVID-19 Update: Focus On the Good (Or At Least Better) News
Another Look at the Current Migraine Scene
Thinking about COVID-19 almost gives me a migraine, or at least a heavy and achy sensation in my noggin – perhaps not an actual migraine, thankfully, but threatening and unpleasant all the same. Happily, thinking about migraines will not give me COVID-19. But migraines are by no means a topic of no consequence, […]
13 Comments Read MoreWhat’s that “First and Best Drugs” Alzheimer’s Stock for 300% gains?
What's teased as the latest Alzheimer's Disease recommendation from Dave Lashmet for Stansberry's Investment Advisory?
13 Comments Read MoreWarm Bits for a Cold Month
Alzheimer’s Disease: 2019 Refresher and Updates
Combating Cancer: The Current Battle Plan
Looking Backward – And a Peek in the Other Direction
Doc Gumshoe looks at the state of cancer treatment... and some of the interesting drug approvals from 2018
14 Comments Read MoreBest Teaser Stocks of the Year
We have a couple traditions here at Stock Gumshoe… we call out one of the worst teaser stock ideas around Thanksgiving and identify the “Turkey of the Year,” and then, as the year comes to a close and holiday merriment washes all around us, we call attention to the best teaser stocks of the year. […]
9 Comments Read MoreMigraine Update
“Rising Healthcare Demand Enables 100+ Year Dividend-Paying Pharma Giant to Enter Best Dividend Stocks List”
Every now and then a reader sends in a question about one of the stock ideas teased by dividend.com, which is a service that looks for, you guessed it, dividend paying stocks. Their standard “tease” is that they send around some hints about the latest stock they’ve added to one of their “best” lists, but […]
8 Comments Read MoreHow Concerned Do We Need to Be About Drug Side Effects?
Two Flubs and a Big Question Mark
Alzheimer’s Wrap-Up
Special Bulletin: The CoLucid IPO
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. You can see all of his articles archived here. Enjoy!] CoLucid Pharmaceuticals, which recently moved from Durham, NC, to Cambridge, MA, plans an initial public offering. Recent news suggests the […]
Leave a comment Read MoreThe Long Case for Receptos
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Gumshoe Irregulars. He has agreed to our trading restrictions, he chooses his own topics, and his words and opinions are his own. Enjoy!] OK, admit it….how many of you have seen the campy films of Baltimore director John Waters? The ones starring the […]
885 Comments Read MoreCancer Care: Where Are We and Where Are We Headed?
[ed note: Michael Jorrin is a longtime medical writer (not a doctor) who covers health and medical topics and trends for our readers, generally without an investment thesis. His words are his own, enjoy!] In the Doc Gumshoe blog about cancer that appeared in June of 2013 (you can check it out here), I commented […]
36 Comments Read MoreThe Finale is Grand: The Gain from Pain Mainly Explained
Payola from Portola?
In his tearjerker “Sisters of Mercy,” Leonard Cohen sings, I’ve been where you’re hanging and think I can see how you’re pinned. Although I am less inclined to bash the FDA than many, it has recently let modern medical practice place many patients in an undesirable situation. What if there was a very powerful drug, […]
932 Comments Read MoreBiosimilars: What Are They, and Why On Earth Should We Care?
Will This Unknown Boston Biotech Make Present Surgical Techniques Obsolete?
Where is the Management of Type 2 Diabetes Heading?
[ed note: Michael Jorrin, a medical writer who we have dubbed “Doc Gumshoe” (he’s not a doctor), shares his thoughts with us once or twice a month — what follows is his latest missive, the words and opinions below are his alone.] I didn’t plan it this way, but the timing of this Doc Gumshoe […]
64 Comments Read MoreAntibiotics Don’t Get No Respect, But You Can Still Profit From Them
Alzheimer’s Disease: Are There Any Glimmers of Light?
[Ed. note: Michael Jorrin, who we like to call “Doc Gumshoe,” is not a doctor, he is a longtime medical writer who contributes pieces for us that we hope give a good background or perspective on medical issues (and marketing) for those of us who are as overwhelmed with “live to 150” promises as we […]
39 Comments Read MoreCan you really “Create Extra Paychecks Month After Month Thanks to the ‘MCR Plan?'” (Leeb)
Figuring out the "Income Stacking" picks teased by Stephen Leeb's Complete Investor
5 Comments Read MoreWe use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
Glad you were smarter than I was about LLY, never ended up buying it myself.I think Fluence is in decent shape, as...
I always get nervous when I find myself at odds with your wisdom. FLNC sits in an investment theme I feel strongly abo...
Almost certainly Eli Lilly's (LLY) Mounjaro (tirzepatide), Tilson has been talking up the weight loss drugs for a year o...
Yup moderrock, Viking looks very interesting. I've been following LLY and NVO for over a year and have done quite nice...
Looks like you had awfully good timing, with their Alzheimer's drug results helping spike the shares higher! Expensive ...
Haven't dug deep in either, my sense is that both LLY and NVO are expensive, but justifiably so, because of the massive ...
Travis: Thank you for the venture funding update and some background on Denali Therapeutics and their scientific resear...
I’m a “value investor”, retired, manage my own investment portfolio, and been a subscriber to Dr Eifrig ‘s new...
Promis Neurosciences (ARFXF) is tackling ALS, Alzheimer’s and Parkinson’s disease. I don’t know why these guys ar...
Latest News. Maybe, perhaps Lilly Strikes Collaboration With Swiss Biotech Basilea In Stomach Cancer StudyEli Lill...
That's what I'm seeing on the CDC site too - diabetes. And Eli Lilly bought a glucagon nasal spray from a small company ...
Eli Lilly finally published its disastrous EXPEDITION3 data, a costly lesson in rethinking Alzheimer’s https://twitt...